Personalis Data Highlights Early Cancer Recurrence Detection
Clinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read More
Search Results for: lung cancer
FDA Approves New Companion Diagnostics for Prostate Cancer Treatment
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read More
Large Study Shows Multi-Cancer Early Detection Test Increases Cancer Detection
Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read More
DELFI Diagnostics Receives New York State Approval for Lung Cancer Blood Test
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read More
FDA Approves Companion Diagnostic to Identify NSCLC Patients Eligible for Tepmetko
The tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read More